Krka Settles Out of Court over Donepezil Marketing in Norway
Ljubljana, 24 February - Drug maker Krka and its subsidiary Krka Sverige AB reached on Wednesday an out-of-court settlement with Eisai Co., Ltd. and Pfizer AS, the parent company said in a press release. Krka will receive EUR 1.55m and will continue to market its Donepezil Krka, used to treat Alzheimers disease, in Norway.
The rest of this news item is available to subscribers.
The news item consists of 427 characters (without spaces) or 85 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.